Vericel Corporation
VCEL
Rank in Stocks
#4674
Vericel Corporation operates as a biopharmaceutical firm that has reached the... Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Share Price
$58.39
Last synced: 2026-11-09
Market Cap
$2.99B
Change (1 day)
6.90%
Change (1 year)
42.24%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vericel Corporation (VCEL)
Category
Healthcare
Operating Margin for Vericel Corporation (VCEL)
Operating Margin as of November 2026 TTM: 5.95%
According to Vericel Corporation's latest financial reports, its current operating margin (TTM) is 5.95%. At the end of 2025 the company had an operating margin of 4.00%.
Operating Margin history for Vericel Corporation from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 5.95% | 48.75% |
| 2025 | 4.00% | 110.53% |
| 2024 | 1.90% | -158.10% |
| 2023 | -3.27% | -68.50% |
| 2022 | -10.38% | 106.36% |
| 2021 | -5.03% | -363.35% |
| 2020 | 1.91% | -120.00% |
| 2019 | -9.55% | 122.09% |
| 2018 | -4.30% | -81.66% |
| 2017 | -23.44% | -33.77% |
| 2016 | -35.39% | 8.62% |
| 2015 | -32.58% | -60.14% |
| 2014 | -81.73% | -99.93% |
| 2013 | -110,336.84% | -31.37% |
| 2012 | -160,761.90% | -0.35% |
| 2011 | -161,333.33% | 706.49% |
| 2010 | -20,004.49% | 392.12% |
| 2008 | -4,064.94% | 43.02% |
| 2007 | -2,842.19% | 38.32% |
| 2006 | -2,054.81% | 50.42% |
| 2005 | -1,366.01% | 66.89% |
| 2004 | -818.51% | -28.88% |
| 2003 | -1,150.83% | 21.88% |
| 2002 | -944.24% | 29.03% |
| 2001 | -731.81% | -13.72% |
| 2000 | -848.17% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -93.51% |
US
|
|
| -149.01% | -125.04% |
US
|
|
| 25.57% | -95.70% |
AU
|
|
| 31.23% | -94.75% |
BE
|
|
| 29.35% | -95.07% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Vericel Corporation's operating margin
What is Vericel Corporation's operating margin?
Vericel Corporation's operating margin is 5.95%, as of Nov 2026.
What was Vericel Corporation's operating margin in 2025?
In 2025, Vericel Corporation's operating margin was 4.00%, compared with 1.90% in 2024.
How has Vericel Corporation's operating margin changed since 2020?
From 2020 to 2025, Vericel Corporation's operating margin was highest in 2025 (4.00%) and lowest in 2022 (-10.38%).
How does Vericel Corporation's operating margin compare with similar companies?
Vericel Corporation's operating margin (5.95%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.